Innovent's PD-1 Inhibitor leads to 22.7% ORR in Phase Ib for NETs

Innovent Biologics Inc. (Suzhou, China) said anti-PD-1 antibody sintilimab (IBI308) led to an objective response rate (ORR) of 22.7% in 22 evaluable patients with neuroendocrine tumors (NETs) who failed standard therapy in a Chinese Phase Ib trial. Data were presented at the Chinese Society of Clinical Oncology meeting in Xiamen.

In 19 evaluable patients with poorly differentiated neuroendocrine carcinoma, sintilimab led to an ORR of 26.3%. As of a June 28 data cutoff, median duration of response was 5.8 months and progression-free survival (PFS) was 2.2 months. Median overall survival (OS) has not yet been reached...